Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial
Publication date: November 2026 Source: The Lancet Rheumatology, Volume 8, Issue 11 Author(s): Robert J Benschop, Jay L Tuttle, Paul Emery, Christoph Preuss, Ching-Yun Chang, Evan B Wang, Narayanan B Perumal, Jonathan T Sims, Ernst R Dow, Ajay Nirula, Pia P Yachi
Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial. // The Lancet Rheumatology. – URL: https://www.sciencedirect.com/science/article/pii/S2665991326002183?dgcid=rss_sd_all
Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial. The Lancet Rheumatology. https://www.sciencedirect.com/science/article/pii/S2665991326002183?dgcid=rss_sd_all
“Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial.” The Lancet Rheumatology.
@article{article69289,
title = {Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial},
journal = {The Lancet Rheumatology},
url = {https://www.sciencedirect.com/science/article/pii/S2665991326002183?dgcid=rss_sd_all}
}